CDTX (Cidara Therapeutics, Inc.) Stock Analysis - Analyst Ratings

Cidara Therapeutics, Inc. (CDTX) is a publicly traded Healthcare sector company. As of May 21, 2026, CDTX trades at $221.38 with a market cap of $6.96B and a P/E ratio of -8.28. CDTX moved +0.03% today. Year to date, CDTX is +228.02%; over the trailing twelve months it is +731.63%. Its 52-week range spans $10.14 to $221.42. Analyst consensus is buy with an average price target of $221.50. Rallies surfaces CDTX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What do analysts rate CDTX?

11 analysts cover CDTX: 1 strong buy, 7 buy, 3 hold, 0 sell, and 0 strong sell. The consensus rating is buy. The average price target is $221.50.

CDTX Key Metrics

Key financial metrics for CDTX
MetricValue
Price$221.38
Market Cap$6.96B
P/E Ratio-8.28
EPS$-26.75
Dividend Yield0.00%
52-Week High$221.42
52-Week Low$10.14
Volume2.69M
Avg Volume0
Revenue (TTM)$1.27M
Net Income$-169.83M
Gross Margin0.00%

CDTX Analyst Consensus

11 analysts cover CDTX: 1 strong buy, 7 buy, 3 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $221.50.

Recent CDTX Insider Trades

  • Ward Shane sold 9.96K (~$2.19M) on Dec 10, 2025.
  • Davarpanah Nicole Negar sold 474 (~$29.80K) on Sep 11, 2025.
  • RA CAPITAL MANAGEMENT, L.P. bought 2.27M (~$100.00M) on Jun 26, 2025.

Common questions about CDTX

What do analysts rate CDTX?
11 analysts cover CDTX: 1 strong buy, 7 buy, 3 hold, 0 sell, and 0 strong sell. The consensus rating is buy. The average price target is $221.50.
Does Rallies show CDTX price targets?
Yes. Rallies tracks CDTX analyst ratings, consensus rating, average price target, upgrades, downgrades, analyst firms, and recent price target changes when available.
Is CDTX research on Rallies investment advice?
No. Rallies provides research, data, and educational context for CDTX. It does not provide personalized investment advice.
CDTX

CDTX